Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia.

According to the deal, Everest is entitled to receive an upfront payment of $280m from Gilead. 

Furthermore, Gilead will make potential payments of up to $175m to Everest on meeting certain regulatory and commercial milestones.

Gilead will also have a chance to hire Everest staff working on the Trodelvy programme. 

A first-in-class Trop-2 directed antibody-drug conjugate, Trodelvy is made with a hydrolyzable linker joined to a topoisomerase I inhibitor payload, SN-38. 

It is indicated to treat adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in mainland China and Singapore.

These patients should have previously received two or more systemic therapies, a minimum of one for metastatic disease. 

Subject to necessary closing conditions and approvals, the deal is anticipated to conclude later this year.

Gilead is also collaborating with regulatory authorities in South Korea, Taiwan and Hong Kong, where New Drug Applications submitted by Everest Medicines for metastatic TNBC are being reviewed. 

Everest and Immunomedics signed an agreement in April 2019, through which the former obtained an exclusive licence for developing and marketing Trodelvy in Greater China, South Korea, Singapore, and Indonesia, excluding Japan. 

The therapy will also be marketed in Vietnam, the Philippines, Thailand, Malaysia and Mongolia.

In October 2020, Gilead took over Immunomedics and created a wide-ranging global clinical development programme, including an investigation of Trodelvy as a single agent and in new combinations across various disease regions. 

Gilead Sciences Oncology Clinical Research senior vice-president Bill Grossman said: “Trodelvy is approved for second-line metastatic TNBC in over 35 countries. 

“We look forward to rapidly advancing our development programme in Asia and to realising the clinical potential of Trodelvy across diverse tumour types.”

Earlier this month, the company entered a definitive agreement to acquire MiroBio for nearly $405m in cash.